Related references
Note: Only part of the references are listed.Association Between Pancreatitis and Subsequent Risk of Pancreatic Cancer: a Systematic Review of Epidemiological Studies
Gui-Xian Tong et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
GENE THERAPY WITH ALIPOGENE TIPARVOVEC (GLYBERA®) FOR THE PREVENTION OF LPLD INDUCED PANCREATITIS: FOLLOW-UP DATA SUGGESTS LONG-TERM CLINICAL BENEFIT
D. Gaudet et al.
ATHEROSCLEROSIS (2014)
Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPLS447X) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy
Valerie Ferreira et al.
HUMAN GENE THERAPY (2014)
Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera)
Florence Salmon et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
Immune responses to AAV-vectors, the Glybera example from bencn to bedside
Valerie Ferreira et al.
FRONTIERS IN IMMUNOLOGY (2014)
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D. Gaudet et al.
GENE THERAPY (2013)
A largely random AAV integration profile after LPLD gene therapy
Christine Kaeppel et al.
NATURE MEDICINE (2013)
Gene therapy for lipoprotein lipase deficiency
Daniel Gaudet et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
New lipid-lowering drugs: an update
A. S. Wierzbicki et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients
Andre C. Carpentier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union
Seppo Ylae-Herttuala
MOLECULAR THERAPY (2012)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency
Daniel Gaudet et al.
ATHEROSCLEROSIS SUPPLEMENTS (2010)
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells
Federico Mingozzi et al.
BLOOD (2009)
Intramuscular Administration of AAV1-Lipoprotein LipaseS447X Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients
Erik S. Stroes et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Adeno-associated virus LPLS447X gene therapy in LDL receptor knockout mice
Jaap Rip et al.
ATHEROSCLEROSIS (2007)
CD8+ T-cell responses to adeno-associated virus capsid in humans
Federico Mingozzi et al.
NATURE MEDICINE (2007)
AAV1-LPL S447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice
Jaap Rip et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2006)
Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation
Colin J. D. Ross et al.
HUMAN GENE THERAPY (2006)
Gene therapy for lipoprotein lipase deficiency: Working toward clinical application
J Rip et al.
HUMAN GENE THERAPY (2005)
Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation
CJD Ross et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Share Paper
